Artal Group’s Ovid Therapeutics OVID Stock Holding History

Artal Group’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,500,000	Closed	-$1.92M	–	65
2024 Q2	$1.92M	Hold	2,500,000	–	–	0.05%	77
2024 Q1	$7.63M	Hold	2,500,000	–	–	0.19%	52
2023 Q4	$8.05M	Hold	2,500,000	–	–	0.27%	40
2023 Q3	$9.6M	Hold	2,500,000	–	–	0.41%	38
2023 Q2	$8.2M	Hold	2,500,000	–	–	0.25%	56
2023 Q1	$6.45M	Hold	2,500,000	–	–	0.38%	55
2022 Q4	$4.65M	Hold	2,500,000	–	–	0.26%	65
2022 Q3	$4.6M	Hold	2,500,000	–	–	0.2%	63
2022 Q2	$5.38M	Hold	2,500,000	–	–	0.29%	56
2022 Q1	$7.85M	Hold	2,500,000	–	–	0.33%	60
2021 Q4	$8.03M	Hold	2,500,000	–	–	0.22%	78
2021 Q3	$8.4M	Hold	2,500,000	–	–	0.19%	89
2021 Q2	$9.78M	Hold	2,500,000	–	–	0.2%	90
2021 Q1	$10.1M	Hold	2,500,000	–	–	0.18%	98
2020 Q4	$5.78M	Hold	2,500,000	–	–	0.12%	103
2020 Q3	$14.3M	Buy	+2,500,000	New	+$16.7M	0.35%	62

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group's OVID Position: Q3 2024 in Review

Artal Group sold out of Ovid Therapeutics (OVID) in Q3 2024, closing a stake of 2,500,000 shares — an estimated $1.92M sold.

Artal Group first reported a position in OVID in Q3 2020 and held it in 16 quarters. The position peaked at $14.3M in Q3 2020. 75 funds tracked by Wall St. Rank hold OVID as of Q3 2024.

Artal Group reported no remaining Ovid Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 2,500,000 Ovid Therapeutics shares in Q3 2024, an estimated $1.92M.
Artal Group first reported a position in Ovid Therapeutics in Q3 2020 and held it in 16 quarters.
Artal Group's Ovid Therapeutics position peaked at $14.3M in Q3 2020.
75 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.